Ra. Nagourney et al., Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients, J CL ONCOL, 18(11), 2000, pp. 2245-2249
Purpose: To determine the safety and efficacy of gemcitabine plus cisplatin
for patients with relapsed adenocarcinoma of the breast.
Patients and Methods: Previously treated patients with adenocarcinoma of th
e breast received cisplatin (30 mg/m(2)) plus gemcitabine (1,000 mg/m(2)) o
n days 1, 8, and 15 of each 28-day cycle, which was changed after patient n
o. 12 to cisplatin (30 mg/m(2)) plus gemcitabine (750 mg/m(2)) days 1 and 8
of each 21-day cycle.
Results: Of 30 patients, three (10%) had complete and 12 (40%) had partial
responses, for an overall response rate of 50%. Two objective responses wer
e observed among the four patients accrued after relapse that followed high
-dose/stem-cell therapies, The median time to progression was 14 weeks. The
median time to progression for objective responders was 23.5 weeks, with a
range of 8 to 68 weeks. Toxicities included grades III and IV neutropenia
in 13%, anemia in 6%, thrombocytopenia in 31%, grade III nausea in 4%, and
grade II peripheral neuropathy in 2% of 151 treatment cycles. Moderate alop
ecia occurred in four patients. There were no treatment-related deaths.
Conclusion: Cisplatin plus gemcitabine is active and tolerable for patients
with relapsed breast cancer. Responses observed in previously treated pati
ents, including high-dose/stem-cell failures, indicate activity in otherwis
e drug-refractory patients. J Clin Oncol 18:2245-2249, (C) 2000 by American
Society of Clinical Oncology.